Capacity expansion
As filed · Senores Pharmaceuticals Limited has informed the Exchange about Capacity expansion
BusinessMinormateriality 59 out of 100
What happened
FactCapacity expansion. capacity expansion in their existing manufacturing facilities. The details of the indicative capacity expansions.
Why it matters
CapitSignal interpretationNew capacity spends capital now for volume later; the commissioning date is the commitment that can be checked against subsequent filings.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
RevisedEarlierQ1 FY27
EBITDA margins stood at almost 30%, improving by 810 bps Y-o-Y.
NowQ1 FY27
Consolidated EBITDA for Q1 of FY27 stood at INR54 crores, growing by a robust 87% on a Y-o-Y basis.
Change
FactTarget revision
Implication
CapitSignal interpretationThe stated figure moved 190.00%.confidence 60%
Watch next
Fact- Stated commissioning date
- Capital outlay and how it is funded
- Expected asset turns at full utilisation
- Based on the current business outlook and execution visibility, we expect the revenue growth of approximately (management committed by FY27)
- FY’27. So, next year, FY’27, we feel that margin when we get to about 18%, 20% to 22% kind of a number should (management committed by FY27)
Evidence
- Senores Pharmaceuticals Limited has informed the Exchange about Capacity expansion(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q4 FY25
How CapitSignal classified this
- Reasoning:
- CAPACITY_EXPANSION base 54; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%